Another subunit vaccine using both recombinant gD2 and gB2 with a different adjuvant (MF59) demonstrated minimal efficacy at preventing infection between HSV-2 discordant partners (13%) and participants attending a sexually transmitted disease clinic (<5%) over 18 months of observation (Table 1) [75,76]. Here, GABBR2 is linked to sexually transmitted disease.